This article is sponsored by Harper Clinic, a Utah-based clinic offering FDA-approved TMS therapy for treatment-resistant ...

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

People who have experienced adverse childhood experiences are at increased risk of developing depression later in life that ...

The order calls for the FDA to give expedited consideration to certain psychedelic drugs.

The order aims to accelerate research and approval of psychedelic-based therapies to help treat mental health conditions ...

Experts say President Trump's order, paving the way for scientists to study psychedelic drugs for mental health treatment, ...

Presently almost all psychedelic drugs in the United States are considered Schedule I controlled substances, in the same ...

Texas lawmakers are eyeing clinical trial for ibogaine as President Trump signed an executive order to speed up research into ...

Donald Trump backs psychedelic research, boosting funding, access, and acceptance of psilocybin and MDMA therapies for ...

U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic ...

The list of products receiving FDA Commissioner priority review vouchers will grow this week to include three psychedelic ...